AbbVie: Neoplasm Metastasis trials

The registry lists 19 Neoplasm Metastasis studies with AbbVie as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 1Phase 2 7Phase 3 8No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary HypogonadismCompletedNCT01739595Phase 3Results posted
• Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung CancerCompletedNCT01657799Phase 2Results posted
• Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary HypogonadismCompletedNCT01534208Phase 3Results posted
• Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary HypogonadismCompletedNCT01532414Phase 3Results posted
• The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)CompletedNCT01386606Phase 2Results posted
• Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary HyperparathyroidismCompletedNCT01341782Phase 3Results posted
• Normalization of Morning Testosterone Levels in Men With Secondary HypogonadismCompletedNCT01270841Phase 2Results posted
• Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on DialysisCompletedNCT01265992Results posted
• Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)CompletedNCT01224782Results posted
• Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes MellitusCompletedNCT01191320Phase 2Results posted
• To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical TestosteroneCompletedNCT00706719Phase 2Results posted
• Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerActive, not recruitingNCT03539536Phase 2
• An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary HypogonadismCompletedNCT01739582Phase 3
• A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary HyperparathyroidismCompletedNCT01149291
• Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary HypogonadismCompletedNCT01067365Phase 3
• Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary HypogonadismCompletedNCT00962637Phase 3
• A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain MetastasesCompletedNCT00649207Phase 1
• Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain MetastasesTerminatedNCT00121420Phase 2
• Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)CompletedNCT00054795Phase 3